NOVABAY PHARMACEUTICALS INC (NBY) Stock Price, Forecast & Analysis
USA - NYSEARCA:NBY - US66987P4090 - Common Stock
NBY Key Statistics, Chart & Performance
The current stock price of NBY is 1.07 USD. In the past month the price decreased by -16.15%. In the past year, price increased by 60.06%.
NBY Latest News, Press Relases and Analysis
NBY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.11 | 980.50B | ||
| JNJ | JOHNSON & JOHNSON | 19.2 | 479.96B | ||
| MRK | MERCK & CO. INC. | 10.89 | 239.57B | ||
| PFE | PFIZER INC | 7.89 | 143.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.21 | 96.25B | ||
| ZTS | ZOETIS INC | 18.63 | 52.34B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.46B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.08 | 10.53B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.3 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.39B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.05B |
Related stock screener links
About NBY
Company Profile
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The company went IPO on 2007-10-26. The firm manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Company Info
NOVABAY PHARMACEUTICALS INC
2000 Powell St Ste 1150
Emeryville CALIFORNIA 94608 US
CEO: Justin Hall
Employees: 14
Phone: 15108998800
NOVABAY PHARMACEUTICALS INC / NBY FAQ
Can you describe the business of NOVABAY PHARMACEUTICALS INC?
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The company went IPO on 2007-10-26. The firm manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
What is the current price of NBY stock?
The current stock price of NBY is 1.07 USD. The price decreased by -1.83% in the last trading session.
Does NBY stock pay dividends?
NOVABAY PHARMACEUTICALS INC (NBY) has a dividend yield of 77.67%. The yearly dividend amount is currently 0.
How is the ChartMill rating for NOVABAY PHARMACEUTICALS INC?
NBY has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does NOVABAY PHARMACEUTICALS INC belong to?
NOVABAY PHARMACEUTICALS INC (NBY) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy NBY stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NBY.
Can you provide the market cap for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) has a market capitalization of 6.43M USD. This makes NBY a Nano Cap stock.
NBY Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NBY. When comparing the yearly performance of all stocks, NBY is one of the better performing stocks in the market, outperforming 92.54% of all stocks.
NBY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBY. NBY has a bad profitability rating. Also its financial health evaluation is rather negative.
NBY Financial Highlights
Over the last trailing twelve months NBY reported a non-GAAP Earnings per Share(EPS) of -7.41. The EPS increased by 84.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -251.48% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBY Forecast & Estimates
5 analysts have analysed NBY and the average price target is 0.87 USD. This implies a price decrease of -18.97% is expected in the next year compared to the current price of 1.07.
For the next year, analysts expect an EPS growth of 39.01% and a revenue growth 11.73% for NBY